25,628 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. bought a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 25,628 shares of the company’s stock, valued at approximately $6,273,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Axsome Therapeutics by 4.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company’s stock worth $2,557,000 after acquiring an additional 1,002 shares in the last quarter. Jones Financial Companies Lllp increased its stake in Axsome Therapeutics by 2,407.9% during the 1st quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company’s stock worth $889,000 after purchasing an additional 7,320 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Axsome Therapeutics by 38.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock worth $35,189,000 after buying an additional 84,151 shares during the period. Caxton Associates LLP bought a new position in Axsome Therapeutics in the first quarter valued at approximately $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Axsome Therapeutics by 29.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company’s stock valued at $8,735,000 after buying an additional 17,250 shares during the period. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Price Performance

Shares of NASDAQ AXSM opened at $199.02 on Friday. The firm has a fifty day simple moving average of $227.43 and a 200 day simple moving average of $206.72. Axsome Therapeutics, Inc. has a twelve month low of $112.90 and a twelve month high of $260.19. The company has a market capitalization of $10.42 billion, a PE ratio of -53.07 and a beta of 0.65. The company has a quick ratio of 1.34, a current ratio of 1.43 and a debt-to-equity ratio of 1.52.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, August 10th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.10). The business had revenue of $218.38 million for the quarter, compared to the consensus estimate of $221.11 million. Axsome Therapeutics had a negative return on equity of 265.55% and a negative net margin of 24.68%. On average, sell-side analysts forecast that Axsome Therapeutics, Inc. will post -2.8 EPS for the current year.

Insider Activity

In related news, Director Susan Mahony sold 300 shares of the firm’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $237.21, for a total value of $71,163.00. Following the completion of the sale, the director owned 1,129 shares of the company’s stock, valued at $267,810.09. This trade represents a 20.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Nick Pizzie sold 33,000 shares of the stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $240.09, for a total value of $7,922,970.00. Following the completion of the transaction, the chief financial officer owned 42,867 shares of the company’s stock, valued at approximately $10,291,938.03. This trade represents a 43.50% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 194,766 shares of company stock worth $45,284,886. Company insiders own 20.60% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $272.00 price objective on shares of Axsome Therapeutics in a research report on Monday, May 4th. Robert W. Baird upped their price objective on Axsome Therapeutics from $241.00 to $246.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 5th. Zacks Research raised Axsome Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 18th. TD Cowen raised their price target on shares of Axsome Therapeutics from $275.00 to $300.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th. Finally, HC Wainwright restated a “buy” rating on shares of Axsome Therapeutics in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Axsome Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $267.60.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.